Objective: Reliable biomarkers associated with aggressiveness of non-functioning gonadotroph adenomas (GAs) are lacking. As the growth of tumor remnants is highly variable, molecular markers for growth potential prediction are necessary. We hypothesized that fast-and slow-growing GAs present different gene expression profiles and reliable biomarkers for tumor growth potential could be identified, focusing on the specific role of epithelial-mesenchymal transition (EMT). Design and methods: Eight GAs selected for RNA sequencing were equally divided into fast-and slow-growing group by the tumor volume doubling time (TVDT) median (27.75 months). Data were analyzed by tophat2, cufflinks and cummeRbund pipeline. 40 genes were selected for RT-qPCR validation in 20 GAs based on significance, fold-change and pathway analyses. The effect of silencing MTDH (metadherin) and EMCN (endomucin) on in vitro migration of human adenoma cells was evaluated. Results: 350 genes were significantly differentially expressed (282 genes upregulated and 68 downregulated in the fast group, P-adjusted <0.05). Among 40 selected genes, 11 showed associations with TVDT (−0.669<R<−0.46, P < 0.05). These were PCDH18, UNC5D, EMCN, MYO1B, GPM6A and six EMT-related genes (SPAG9, SKIL, MTDH, HOOK1, CNOT6L and PRKACB). MTDH, but not EMCN, demonstrated involvement in cell migration and association with EMT markers. Conclusions: Fast-and slow-growing GAs present different gene expression profiles, and genes related to EMT have higher expression in fast-growing tumors. In addition to MTDH, identified as an important contributor to aggressiveness, the other genes might represent markers for tumor growth potential and possible targets for drug therapy.
Introduction
The pathogenesis of sporadic non-functioning pituitary adenomas (NFPAs) remains elusive. Regardless of intensive effort, specific genetic mutations are rarely found in NFPAs (1). There are no reliable molecular markers associated with aggressiveness or recurrence, making the prediction of tumor behavior a demanding challenge. Consequently, prolonged observation is necessary, constituting a significant burden in terms of medical resources and societal costs.
The silent gonadotroph NFPAs (GAs) are the most common (75%) of all the immunohistochemical subgroups of NFPAs (2) . Gene expression profiling analyses have shown to be of importance in identifying molecular markers, as well as to determine essential signaling pathways for correct histological stratification and thereby adequate treatment of a wide range of cancers (3) . Recent studies have investigated the differential gene expression according to tumor invasiveness or recurrence characteristics (i.e. comparing invasive vs non-invasive (4, 5) and early recurrent vs non-recurrent pituitary adenomas (6) ). Tumor volume doubling time (TVDT) describes the growth velocity by measuring the time it takes for a tumor to double in volume. It is calculated presuming the tumor has an exponential growth curve, enabling the clinician to estimate a safe interval between follow-up investigations and is used to predict the clinical course of tumors in several cancer types. Information of adenoma growth kinetics and TVDT, collaborated with data about tumor biology, would substantially enhance the clinical knowledge of tumor behavior and help to adjust and individualize follow-up (7) . Previous studies usually describe the growth of NFPAs by an exponential, logistic or linear growth model (7, 8, 9, 10, 11) . The presence of tumor remnants following initial surgery indicates a high risk of regrowth (12) , and we have recently presented that the calculation of early TVDT as a prediction of 'worstcase' scenario for future growth can be a tool to tailor safe follow-up intervals (13) .
Epithelial-mesenchymal transition (EMT) is a wellstudied regulatory programming process in various cancers, which also plays a role in the pathogenesis of pituitary adenomas (14, 15, 16) . Epithelial cells undergo changes to show mesenchymal cell characteristics with increased motility, invasiveness and even distant metastasis (14, 15, 16) . Loss of membranous E-cadherin is a hallmark of EMT (14) . Studies of growth hormone and ACTH-producing adenomas have linked EMT to the progression of tumors. The reduction in E-cadherin content in these tumors has been associated with tumor size, invasiveness and poor response to medical treatment (15, 17, 18, 19, 20) .
In this study, we hypothesized that GAs with different initial growth velocities (high vs low) have different gene expression profiles. We aimed to identify target genes in fast-and slow-growing tumors, estimated by early postoperative TVDT, and to find reliable biomarkers predicting growth potential of the residual tumor tissue, focusing on the specific role of EMT.
Subjects and methods

Patients and samples
The patients included in this study (n = 20) were selected from a larger cohort of patients (n = 88) based on the possibility to assess growth modeling (only tumors with regrowth and four or more consecutive magnetic resonance imaging (MRI) examinations or five years of follow-up, not interrupted by new interventions), the availability of stored tumor tissue and the positivity for gonadotroph hormones (follicle-stimulating hormone (FSH) and/or luteinizing hormone (LH)) and/or steroidogenic factor (SF)-1 on immunohistochemistry (IHC). Tumor volume, early TVDT and growth models (logistic, exponential or linear) were estimated for all samples (13) . The patients underwent surgery at Oslo University Hospital between 2002 and 2009, and all samples were from the primary operation. The tumor tissue was immediately placed on ice and snap frozen in liquid nitrogen, and later stored at −80°C or embedded in Tissue-Tek.
Written informed consent was obtained from all patients. The study was approved by the regional ethics committee (REK no: 2014/635 and REK no: 2014/1680) and hospital authority. The genetic expression analyses were exclusively connected to tumor biology. Thus, no information about the patient's genotype was given, and the study did not influence treatment or patient follow-up.
RNA isolation and reverse transcription
After homogenization of tumor tissue, total RNA was extracted using TRIzol (Invitrogen) and later purified with the QIAGEN miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, including the DNase digestion step for removal of genomic DNA. RNA integrity was determined by Agilent 2100 Bioanalyzer (Agilent Technologies) and the concentrations were measured by OD readings on a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). All samples had RNA integrity numbers (RIN) >7, indicating an adequate quality. A high-capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to perform reverse transcription in a Labnet MultiGene Gradient Thermal Cylinder (Labnet International, Edison, NJ, USA) using 1 μg RNA in reaction. After the reaction, the cDNA was diluted 1:10 and all real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) measurements were performed with the same batch of cDNA.
RNA sequencing
Library preparation and sequencing
The RNA sequencing (RNA-seq) was performed using 2 μg RNA for each sample (n = 8) at the Norwegian Sequencing Centre, Oslo, Norway. Eight RNA-seq libraries with unique indexes were prepared using TruSeq stranded mRNA library prep kit (Illumina, San Diego, CA, USA) by following manufacturer's instructions. Libraries were pooled together, and 125 nt paired end sequencing was performed on two lanes of HiSeq 2500 (Illumina). RTA v1.18.66.3 was used for base calling and was further processed using bc2fastq v2.17.1.14 to demultiplex and generate fastq data based on the indexes used during library preparation.
Data processing
Pre-processing and cleanup Fastq data from two lanes were concatenated for each sample before further analysis. Lowquality reads and adaptors were removed using Trimmomatic v0.33 (21) with recommended parameters. BBMap v34.56 (http://sourceforge.net/projects/bbmap) was used to remove reads aligning to PhiX (RefSeq: NC_001422.1), which was added as a spike-in during sequencing.
Transcriptome alignment Cleaned data were aligned against the Human ensemble GRCh38 genome and the transcriptome using Tophat2, v2.0.13 (22) using '--library-type fr-firststrand --no-mixed --no-novel-juncs --transcriptome-index' as parameters. Library size was estimated using picard, v1.112 (http://broadinstitute. github.io/picard/) CollectInsertSizeMetrics tool after aligning the first one million reads using bowtie, v2.2.3 (23) to Human ensemble GRCh38 cDNA sequences, and the output was also provided as parameters for tophat2 alignment. Cuffdiff, v2.2.1 (24) pipeline was used to calculate the differential expression of the known genes described in ensemble GTF and CummeRbund, v2.14 (25) . R package was used to visualize expression data, and custom scripts were used to create tables and graphs. Gene expression plots were created for both gene and isoform expression. Hierarchical clustering was performed using Pearson correlation with complete linkage in TM4 MeV (http://mev.tm4.org/).
RT-qPCR validation
To verify the expression of the transcripts of the selected genes, RT-qPCR was performed in the ABI 7900 (Applied Biosystems) on the entire cohort (n = 20). Reaction mix (with Power SYBR Green PCR Master Mix, Applied Biosystems) and samples were dispensed in the corresponding wells by an automated pipetting system (epMotion5070 CB, Hamburg, Germany). RT-qPCR amplification was performed as previously described (26) .
We used the primer bank (https://pga.mgh.harvard. edu/primerbank/) or searched the literature to find the primer pairs (Supplementary file 1, see section on supplementary data given at the end of this article), and tested their specificity using BLAST analysis (NCBI). The genomic DNA sequence (downloaded from www.ensembl. org) was used to study exon-intron borders by matching the primers to their location to avoid false-positive amplification due to DNA contamination. Primers that could detect the same isoforms as detected by RNA-seq were carefully selected. Primers' amplification efficiency and correlation coefficients were acquired from the slope of the standard curves. All RT-qPCR experiments were in accordance to the MIQE guidelines. Gene expression was quantified using the delta-delta Ct (ΔΔCt) method. The expression was normalized to the index obtained from the geometric mean of GAPDH and ALAS1 Ct levels, as previously shown to be some of the most stable reference genes in NFPAs, and expressed as relative mRNA levels (26) .
In vitro experiments
Cell cultures
Primary cells were obtained from three patients following a previously described protocol (27) . Briefly, tumor tissue from the primary operation was collected in the operation room in L-15 (Leibovitz) medium (Lonza, cat. no. 12-700F, Verviers, Belgium) and transported on ice. The blood was removed immediately and the tumor cut in small pieces. After washing, the pellet was enzymatically dispersed with papain 13.2 U/mL (Worthington Biochemical Corporation, cat. no. LS003118, Lakewood, NJ, USA) for 3 min at 37°C. The papain was stopped by adding human albumin and removed by washing, and the cells were filtered through 100 μm cell strainer (BD Falcon), counted and plated at ca. . Lastly, we observed that after a few passages, even if the culture was heterogeneous just after the isolation, it became more homogenous and none of the cells had the classical fibroblast appearance. All in vitro studies were performed with 3-4 technical replicates/patient, normalized and the mean of each patient were pooled together to perform data analysis.
Silencing and RT-qPCR
After the cells reached 70-80% confluence, they were transfected with the Lipofectamine RNAiMAX (ThermoFisher Scientific, cat. no. 13778075) and incubated for two or three days before performing the experiments. siRNA (Ambion Silencer Select Pre-designed siRNA, ThermoFisher Scientific) specific for human MTDH, EMCN, GAPDH (as a positive control, Supplementary file 8) and scramble control was used. The sense strand sequence was 5′-GAAUCUCCCAAACAAAUAAtt-3′ for MTDH and 5′-GCUGUUUCAACAUUACAAAtt-3′ for EMCN. The silencing was validated by RT-qPCR and by Western blot (WB) and IHC (Supplementary file 3). Cytotoxicity was measured using Cytotoxicity Detection Kit (Sigma-Aldrich cat. no. 11644793001).
WB
Protein extraction reagents were from ThermoFisher Scientific. The cells, kept on ice, were washed with cold PBS, lysed using 100 μL/well M-PER (cat. 
Wound healing assay
Images were taken with Motic AE200, objective motic 4×, ocular motic N-WF 10×, mitocam 2300 after the scratch was made, as well as every 3rd to 12th hour depending on the observed migration rate, until the wound was completely healed or up to 33 hours when silencing was expected to lose its function. Cell migration (µm between wound borders) was measured using Fiji ImageJ (https:// imagej.net/Fiji/Downloads).
Statistics
All measurements were checked for a normal distribution by visual methods (histograms and Q-Q plots). The data are presented as means ± s.e.m. or as medians and IQR for continuous variables and as counts for categorical data. Differences in patient demographics were analyzed by Mann-Whitney U test. A non-parametric univariate association analysis was used to quantify bivariate independent associations. One-way ANOVA and unpaired Student's sample t test (two-tailed) were used to evaluate the differences between silenced cells and scramble controls. To assess the differences in the wound-healing assay, repetitive measures model with Bonferroni correction was used. The analyses were performed using SPSS, version 21. A P value <0.05 was considered significant .
Results
Characterization of patient samples for RNA-seq and RT-qPCR analysis
The samples included in this study (n = 20) were GAs macroadenomas from the primary operation, and all except two samples showed tumor remnant at three months postoperatively. The samples were divided 
RNA-seq
RNA-seq analysis identified 350 significantly differentially expressed genes (P-adjusted <0.05) between the fast and the slow group (Supplementary file 2): 282 genes were upregulated in the fast group (fold-change between 1.9 and 32.0), and 68 genes were upregulated in the slow group (fold-change between 1.9 and 18.4) (Fig. 1A) . 40 genes were selected for validation and investigation with RT-qPCR based on their significance (P-adjusted <0.05), fold-change, expression plots in each sample (Supplementary file 4) and pathway analyses (g:Profiler, http://biit.cs.ut.ee/gprofiler/). There were no significantly differentially regulated pathways between the fast and the slow group; therefore, we also based the selection on the literature search with the main focus on cancer-and EMTrelated pathways (Fig. 1B and C (Fig. 1C) . Figure 2A shows the associations between selected genes and initial TVDT, pre-and post-operative tumor volume and different imagistic invasiveness parameters in the cohort of GAs. 11 of the 40 genes showed significant negative associations with TVDT (−0.669≤R≥−0.466, P < 0.05) (Fig. 2B ). These were PCDH18, UNC5D, EMCN, MYO1B, GPM6A and six genes known as related to EMT (SPAG9,
RT-qPCR
SKIL, MTDH, HOOK1, CNOT6L and PRKACB).
Preoperative volume was associated with postoperative volume (R = 0.747, P = 0.003). The only gene associated with preoperative volume was FOS (R = 0.609, P = 0.021). There was no significant association between selected genes and gender or age, with ANXA11 as the only exception correlating with age (R = −0.473, P = 0.035). Postoperative tumor volume was negatively associated with HOOK1 (R = −0.525, P = 0.025) and CNOT6L (R = −0.633, P = 0.005), in addition to a positive association with FOS (R = 0.556, P = 0.020). Of these, only CNOT6L was also associated negatively with postoperative invasiveness. Some of the selected genes ( Fig. 2A) showed a positive association with growth models, meaning that they exhibited a low expression in the exponential, an intermediate expression in the linear and a high expression in the logistic growth. We found positive associations with the preoperative invasiveness for ANXA11, LRCH2, KIF5B and FNBP1L and negative associations with MDK, LGALSSBP, WFDC2, FBLN1, P3H3 and BSG. Among these, only LRCH2 and KIF5B (positively), and P3H3 (negatively), remained associated with postoperative invasiveness. There was no difference in gene expression between invasive and non-invasive tumors, with the exception of LRCH2 that was higher expressed in the invasive tumors. Between invasiveness and pre-and post-operative volume no significant association was found. There was no association between the initial TVDT, MTDH, EMCN and MKI67 (Ki-67) and TP53 (tumor protein p53) gene expression (data not shown). 
Silencing MTDH and EMCN in primary human adenoma cells
We chose two genes, MTDH and EMCN, for mechanistic in vitro studies. As depicted in Fig. 2B , both genes showed negative associations with TVDT, higher expression being associated with a lower TVDT (i.e. a more aggressive phenotype). MTDH mRNA gene expression was significantly reduced in siMTDH cells vs scramble controls (81%, P < 0.001) (Fig. 3A) . A significant reduction in protein expression by WB (18%, P = 0.001) (Fig. 3C and D) and IHC (Supplementary file 3) was found. Similarly, a significant reduction in EMCN mRNA gene expression by 68% was observed in siEMCN cells (P = 0.046) (Fig. 3B) . Due to the difficulties with the specific antibodies, we were unable to produce data on WB protein expression for EMCN. LDH cytotoxicity assay showed no significant difference between silenced and scramble control cells after two and three days (Supplementary file 5).
Migration assay
The wound-healing assay was performed to assess cell migration in vitro. It demonstrated that the siMTDH cells migrated at a slower rate in all three patients, even though there was a great difference in cells' behavior between patients (Fig. 4A) . The only significant difference in cell migration for siEMCN cells was recorded after 6 h in patient 73 (Fig. 4B) . Lastly, we calculated the area under the curve (AUC) and found a significant difference between controls and siMTDH cells, but not for siEMCN cells (Fig. 4A and B ).
E-cadherin and N-cadherin
We investigated if the gene expression of the EMT markers CDH1 (E-cadherin) and CDH2 (N-cadherin) would change between siMTDH cells and scramble controls (Fig. 5 ).
In the siMTDH cells, the gene expression of CDH1 was significantly higher (P = 0.004), no significant reduction in expression of CDH2 was observed, but the CDH1/CDH2 ratio was higher (P = 0.039). There was no significant difference between siEMCN cells and scramble controls in gene expression of the two EMT markers (data not showed).
Discussion
The present study demonstrates that fast-and slow-growing human GAs present different gene expression profiles. Of the 350 differently expressed genes, 40 were selected for further validation in a larger cohort of patients, but only 11 showed significant associations with initial TVDT and six of them were related to the EMT process. Some of the selected genes were also correlated to classical MRI invasion parameters, suggesting an additional role behind the involvement in the growth velocity. Furthermore, MTDH, but not EMCN, was involved in pituitary adenoma cell migration in vitro, making its coded protein, metadherin, a valuable biomarker for GAs tumor aggressiveness and regrowth, and a potential medical target. Our study is the first to investigate genome-wide mRNA expression in fast-vs slow-growing GAs. The literature is sparse in this manner and to date two studies analyzed these tumors with some limitations. The first study presented differentially expressed long non-coding RNAs (lncRNA) and mRNAs in GAs vs normal pituitary tissues (28) . In addition to the concern regarding the comparison of a tumor containing mainly of one cellular subtype (i.e. gonadotrophs) to the normal pituitary, comprising at least five different cell types, the authors chose to focus mostly on the lncRNA-mRNA co-expression network in the mTOR pathway, and the data were not evaluated in regards to markers of invasiveness and aggressiveness. The second study performed in multiple endocrine neoplasia X (MENX) affected rats by mRNA Data are presented as mean ± s.e.m.; n = 3 patients, 3-4 technical replicates/patient; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. microarrays affymetrix, again comparing gonadotroph tumors and normal pituitary, identified CYP11A1, a gene regulated by the SF-1, as a promoter of proliferation/ survival of gonadotroph cells both in rats and humans (29) . However, we were unable to find CYP11A1 as one of differentially expressed genes in our study. In addition, two recent studies described invasive-related candidate biomarkers by mRNA microarray in NFPAs, but no data on the histological subtype was presented making it difficult to directly compare the results to our study (5, 30) .
The only study performing whole-exome DNA sequencing in seven sporadic GAs identified 24 somatic mutations in independent genes with no recurrent mutations. Moreover, DNA sequence analysis of these in the validation set did not reveal any mutations, thus indicating that these genes were unlikely to contribute in the etiology of sporadic GAs (31) . Indeed, none of the somatic mutated genes were found to be differently expressed in our study, although our study was not designed to identify genes involved in tumorigenesis, but genes associated with aggressive growth behavior. 
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We mainly looked at the initial TVDT to distinguish between more and less aggressive GAs, based on the fact that initial TVDT might serve as an effective parameter of estimating early growth velocity that can predict the course of tumor remnant (13) . Earlier studies compared invasive and non-invasive tumors based on their cavernous sinus invasion. However, differentiating radiologically between these two categories can be challenging, especially in the beginning of a tumors' invasive course. The growth rate as estimated by TVDT and the threatening of optic nerve and optic chiasm, rather than the lateral invasiveness, represents clinical criteria for tumor aggressiveness and the need for surgery. Despite their limitations, Ki-67 and p53 might be used as markers of aggressiveness and recurrence in pituitary adenomas (32, 33) . However, our study did not find any associations between gene expression of MKI67 and TP53 and TVDT, MTDH and EMCN.
EMT is shown to be of significant importance in the aggressiveness and progression of somatotroph and corticotroph adenomas (15, 17, 18) . However, using our selection criteria, we cannot conclude that EMT is the major component of the tumor growth in gonadotroph adenomas. For the in vitro study, we chose genes that code for proteins possible to target by medical treatment. MTDH is extensively studied in other cancers and its role as an oncogene is recognized (34) . It has recently been shown that Bortezomib treatment can suppress MTDH in multiple myeloma (35) . EMCN is a membrane protein that could, in theory, be easy to approach if proved to be a major actor in pituitary tumorigenesis (36) .
MTDH, a known regulator of EMT (37), was significantly higher expressed in the fast-growing tumors, and the wound-healing assay demonstrated MTDH to be a contributor in cell migration, an important characteristic of mesenchymal cells. Moreover, silencing of MTDH led to a more epithelial and less aggressive profile, reassuring its role. Similarly, a study in human glioblastoma cells showed that knockdown of MTDH increased the expression of E-cadherin and decreased the expression of N-cadherin and also when upregulating MTDH expression the cells showed overexpression of mesenchymal markers (38) . Recent studies have shown that MTDH promotes tumor progression in many cancers types, including breast, prostate, glioma, esophageal and hepatocellular, through the integration of multiple signaling pathways, suggesting that MTDH may represent a potentially valuable target in cancer treatments (34) .
EMCN did not show involvement in cell migration, nor association with EMT markers. It has recently been shown that EMCN prevents leukocyte-endothelial cell adhesion and has a critical role under resting and inflammatory conditions (36) . The lack of effect on cell migration by EMCN could be explained by different means, such as: (1) EMCN does not have a role in cell migration of pituitary adenoma cells and our premises were incorrect, (2) technical challenges related to in vitro culturing did not allow us to adequately silence the EMCN gene such as its effect could be recorded, (3) other cells than pituitary adenoma cells (e.g. endothelial cells) may drive the pituitary adenoma aggressiveness and be responsible for EMCN expression at RNA-seq and RT-qPCR levels, (4) although there is an association with early TVDT, EMCN is not involved in tumor aggressiveness.
The remaining nine genes correlating significantly to the initial TVDT should be further studied, as they might represent useful markers for aggressiveness and tumor growth or targets for potential medical therapy. Three of these genes (SKIL, CNOT6L and HOOK1) code for proteins related to EMT suppression (39, 40, 41) . However, our results somehow contradict their described functions, as the genes were higher expressed in the fast-growing tumors. Two other genes that definitely need further characterization are GPM6A (the highest positive fold of change on RNA-seq) and PCDH18 (the highest association with TVDT). GPM6A is highly expressed in brain tissue and is involved in neuronal differentiation, including differentiation and migration of neuronal stem cells, neuronal plasticity and filopodia outgrowth and motility and probably synapse formation (42) . PCDH18 belongs to the protocadherin gene family and is thought to play a role in the establishment and function of specific cell-cell connections in the brain (43) .
We observed that tumors with high LRCH2 and KIF5B were more invasive, but also easier to remove since they have a negative association with the postoperative invasiveness. Although this is an interesting observation, it should be regarded with caution since other factors Figure 5 Epithelial-mesenchymal transition genes. mRNA levels of CDH1 (E-cadherin) and CDH2 (N-cadherin) and the ratio of CDH1/CDH2 in silenced MTDH (siMTDH) and scramble control (scramble ctrl) cells. GAPDH was used as reference gene. Data are presented as mean ± s.e.m.; n = 3 patients, 4 technical replicates/patient; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. such as perioperative conditions, the operative intention (debulking vs total removal) and patients' age, might have interfered.
When performing RNA-seq studies, a large amount of data is generated, and further investigations with mechanistic in vitro studies are of great value to gain a broader understanding of the importance of the identified genes in the tumor pathology. Accordingly, we carefully selected genes based on various relevant criteria to further test our hypothesis in a larger cohort of adenomas. Interestingly, just one-fourth of our selected genes showed associations with initial TVDT, supporting the RNA-seq data. Another fourth of the selected genes were close to reach statistical significance, suggesting that perhaps a larger cohort of GAs in the validation study would have resulted in a higher number of genes that were in agreement with the hypothesis. However, the rest of the selected genes did not show any association with initial TVDT, being in disagreement with RNA-seq data and emphasizing the need for validation of small RNAseq studies in larger cohorts of patients. Furthermore, when two of the genes were tested in vitro, in a functional assay, in primary human adenoma cells, just one gene (i.e. MTDH) showed to have relevance.
The strengths of the present study are: (1) the thorough clinical, image and immunohistochemical characterization of the cohort, (2) the translational approach and (3) the use of human primary adenoma cells.
Our study has limitations. First, we might have chosen a selected set of tumors. The slowest growing tumors might have ended follow-up before four MRI exams or a five year follow-up was obtained, and the fastest growing tumors might have required re-intervention before the sufficient follow-up. However, these criteria were necessary to compute growth models and initial TVDT (13) . Second, a limited number of samples were sequenced, and the in vitro studies were performed only in three patients. However, the validation study was performed in a larger cohort of GAs. Third, we have deliberately chosen to perform the present study in a well-characterized cohort of GAs and did not include other types of NFPAs. Clear evidence shows that the different NFPA subtypes have different clinical behavior and molecular profiles (44) . Consequently, before extrapolating, further validation of our data should be performed in other subtypes of NFPAs. Fourth, it is not known to date, if the GAs molecular profile, and subsequently the tumor behavior, is similar before and after operation. In this study, initial TVDT was measured retrospectively in postoperative growing remnants and might not accurately reflect the growth potential of the primary tumor. Although this may be regarded as a limitation, we consider that measuring TVDT, even on postoperative recordings, is a more precise approach in characterizing the growth potential of GA, than by the simpler, wider used criteria as macro/microor invasive/non-invasive adenomas. Lastly, although the present study shows in vitro mechanistic data for two selected proteins, we did not acquire protein data in the entire cohort of differentially expressed genes.
In conclusion, fast-and slow-growing tumors have different molecular profiles, but genes identified by RNA-seq need to be further validated in a larger cohort of patients, and with mechanistic studies. MTDH is a promising biomarker in fast-growing GAs and may be considered as a potential drug target.
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